VYNE Therapeutics (VYNE) AI Stock Analysis

• Market Cap: $18.84M
• Dividend Yield: N/A
• Average Volume (3M): 2.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: 6.29%
• EPS Growth: 7.42%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 33,286,423
• 10 Day Avg. Volume: 3,707,448
• 30 Day Avg. Volume: 2,746,500
• PEG Ratio: 0.05
• Price to Book (P/B): 2.74
• Price to Sales (P/S): 284.78
• P/FCF Ratio: -4.19
• Enterprise Value/Market Cap: -0.53
• Enterprise Value/Revenue: -18.92
• Enterprise Value/Gross Profit: -18.92
• Enterprise Value/Ebitda: 0.27
• 1Y Price Target: $2.00
• Price Target Upside: 250.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $0.57 ▼(-0.70% Downside)

The score is held down primarily by very weak fundamentals (minimal revenue, large losses, and heavy cash burn), despite a debt-light balance sheet. Technicals are moderately supportive with improving momentum, and the merger/financing news is a notable positive, but valuation remains challenged due to ongoing losses and no dividend data.

Positive Factors

Strategic Merger

The merger with Yarrow Bioscience provides strategic direction and financial backing, positioning the company to advance its pipeline and improve stockholder value.

Financial Backing

Significant financial backing from investors ensures funding for operations into 2028, supporting long-term R&D and clinical trials, enhancing financial stability.

Pipeline Advancement

Advancing YB-101, a first-in-class antibody, could lead to breakthrough treatments, strengthening market position and driving future revenue growth.

Negative Factors

Persistent Losses

Ongoing financial losses and negative cash flow raise concerns about long-term sustainability, potentially limiting growth and operational capabilities.

Negative Cash Flow

Negative cash flow indicates cash management challenges, necessitating reliance on external financing, which could be risky if market conditions tighten.

Declining Revenue

Declining revenue trends highlight challenges in product adoption and market penetration, potentially impacting future growth and profitability.

VYNE Therapeutics Business Overview & Revenue Model

Company Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

How the Company Makes Money

VYNE Therapeutics primarily generates revenue through the commercialization of its proprietary products and potential partnerships with larger pharmaceutical companies. The company may earn revenue from product sales once its therapies receive regulatory approval and are launched in the market. Additionally, VYNE can also generate income through licensing agreements and collaborations, which may involve upfront payments, milestone payments based on the achievement of development goals, and royalties on future sales. These partnerships provide critical funding and resources to support the company's research and development efforts, while also allowing VYNE to share the financial risks associated with bringing new treatments to market.

VYNE Therapeutics Financial Statement Overview

Summary

Operating performance is very weak: TTM revenue is minimal (~$0.5M) with large ongoing operating/net losses, and cash burn is heavy (TTM operating cash flow and free cash flow around -$38M). The main offset is a low-leverage balance sheet with essentially no debt, but equity/assets have eroded from continued losses.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small (~$0.5M) and, while it shows growth versus the prior annual period, the business remains deeply unprofitable with large operating and net losses. Profitability is structurally weak as losses vastly exceed revenue, and this pattern has persisted across multiple annual periods, indicating limited operating leverage and continued dependence on external funding.

Balance Sheet

The balance sheet is a relative bright spot: debt is essentially zero in the latest periods (including TTM (Trailing-Twelve-Months)), which reduces financial risk and interest burden. However, equity and total assets have declined materially from earlier annual periods, and returns to shareholders are strongly negative due to ongoing losses—highlighting erosion of capital despite low leverage.

Cash Flow

Cash burn remains heavy: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are roughly -$38M, worse than the most recent annual period, and free cash flow growth is negative. While cash outflow roughly tracks net losses (suggesting limited non-cash distortion), the scale of persistent negative free cash flow points to ongoing funding needs and elevated dilution/financing risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	524.00K	501.00K	424.00K	477.00K	931.00K	20.99M
Gross Profit	524.00K	501.00K	424.00K	477.00K	931.00K	19.60M
EBITDA	-36.92M	-43.63M	-29.26M	-34.22M	-38.80M	-251.09M
Net Income	-33.67M	-39.83M	-28.45M	-23.21M	-73.33M	-255.57M
Balance Sheet
Total Assets	36.13M	66.91M	97.69M	40.76M	67.05M	93.74M
Cash, Cash Equivalents and Short-Term Investments	32.70M	61.52M	93.25M	30.91M	42.25M	58.59M
Total Debt	0.00	99.00K	214.00K	0.00	349.00K	34.78M
Total Liabilities	4.04M	14.82M	8.95M	9.56M	18.41M	56.25M
Stockholders Equity	32.09M	52.09M	88.73M	31.20M	48.64M	37.49M
Cash Flow
Free Cash Flow	-38.48M	-34.09M	-25.34M	-29.20M	-56.37M	-137.19M
Operating Cash Flow	-38.36M	-33.97M	-25.34M	-29.20M	-56.37M	-137.08M
Investing Cash Flow	41.65M	23.36M	-57.35M	15.67M	1.03M	89.11M
Financing Cash Flow	-260.00K	-141.00K	82.39M	1.65M	39.78M	61.81M

VYNE Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.57
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Neutral. The current price of 0.57 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.49, and below the 200-day MA of 0.72, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 59.40 is Neutral, neither overbought nor oversold. The STOCH value of 36.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VYNE.

VYNE Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INAB	52 Neutral	$19.24M	-0.30	-189.72%	―	―	70.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYNE	49 Neutral	$18.84M	-0.72	-70.67%	―	6.29%	7.42%
XBIO	42 Neutral	$5.09M	-1.08	-57.43%	―	13.30%	22.70%
KZIA	41 Neutral	$66.43M	-0.48	―	―	-98.25%	63.05%
KALA	40 Underperform	$14.76M	-0.09	―	―	―	52.39%

VYNE Therapeutics Corporate Events

VYNE Therapeutics Announces Merger with Yarrow Bioscience

On December 17, 2025, VYNE Therapeutics and Yarrow Bioscience announced a definitive merger agreement resulting in the creation of a combined entity operating as Yarrow Bioscience, Inc. This merger positions the company to advance Yarrow’s lead program, YB-101, a first-in-class thyroid-stimulating hormone receptor antibody aimed at treating Graves’ disease and thyroid eye disease. Supported by $200 million in pre-closing financings, the combined company’s operations are expected to be funded through 2028, including multiple clinical trials scheduled to begin globally. The merger, approved unanimously by both companies’ boards, signifies a strategic pivot for VYNE to bolster its stockholder value and Yarrow’s pipeline, with leadership from Yarrow executives and significant backing from industry-leading investors.

The most recent analyst rating on (VYNE) stock is a Hold with a $0.36 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.

VYNE Therapeutics Approves Director Elections and Proposals

On December 12, 2025, VYNE Therapeutics Inc. held its annual meeting of stockholders where three proposals were considered. The election of two Class I directors was approved, with Elisabeth Sandoval Little and Steven Basta elected to serve until the 2028 annual meeting. The selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Additionally, stockholders approved the compensation for the company’s named executive officers.

The most recent analyst rating on (VYNE) stock is a Hold with a $0.36 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.